NeuroOne Medical Technologies Corporation announced the appointment of Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at NYSE-listed Penumbra, Inc., where he leads long-range planning, financial planning and analysis, business development, and investor relations for the world's leading thrombectomy company. His appointment represents a strategic move for NeuroOne as it seeks to advance its mission of transforming surgical diagnosis and treatment of neurological disorders.
Mills brings more than two decades of medical technology industry experience to NeuroOne's board, including over 13 years as Managing Director and head of the medical technology equity research practice at Canaccord Genuity. During his tenure as an investment analyst, he prepared financial models and forecasts, published research, and conducted due diligence on dozens of public and private companies in the sector. His analytical work earned him recognition as the #2 ranked Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.
Dave Rosa, CEO of NeuroOne, stated that the company is privileged to welcome Mills with his strong background in med-tech in both corporate settings and as an industry investment analyst. Having known Mills since his time at Canaccord, Rosa emphasized that he brings unparalleled and invaluable experience and insights in med-tech. His firsthand knowledge of the industry, combined with his investment and capital markets expertise, will be a critical resource as NeuroOne progresses on its clinical and corporate goals.
Paul Buckman, Chairman of the Board of Directors, emphasized Mills' expected contributions, noting that in addition to his service on the Compensation and Nominating & Corporate Governance Committees, Mills will help expand the breadth and depth of the company's reach as it transforms the diagnosis and treatment of neurological disorders, positioning NeuroOne to create additional value for shareholders. NeuroOne is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company's technologies aim to improve patient outcomes and reduce procedural costs while potentially pursuing applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information about the company's work, visit https://nmtc1.com.
Mills' appointment comes at a critical time for medical technology companies navigating complex regulatory environments and capital markets. His dual perspective from both the corporate executive and investment analyst sides of the industry provides NeuroOne with unique insights into strategic planning, financial management, and market positioning. This expertise could prove particularly valuable as NeuroOne advances its clinical programs and seeks to maximize shareholder value in the competitive neurological device market. The appointment signals NeuroOne's commitment to strengthening its leadership with industry veterans who can guide the company through both clinical development and financial challenges, positioning it for growth in the expanding neurological treatment sector where companies must balance innovation with regulatory compliance and market realities.
